The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial
Robert Frederich
Diabetology and Metabolic Syndrome
View PDFchevron_right
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
Elizabeth Paz-Pacheco
Diabetes Obesity & Metabolism, 2009
View PDFchevron_right
A Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes
Danshi Li
Diabetes care, 2015
View PDFchevron_right
The role for saxagliptin within the management of type 2 diabetes mellitus: an update from the 2010 European Association for the Study of Diabetes (EASD) 46th annual meeting and the American Diabetes Association (ADA) 70th scientific session
Pablo Aschner
Diabetology & Metabolic Syndrome, 2010
View PDFchevron_right
A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
Robert Lasser
BMC Endocrine Disorders, 2014
View PDFchevron_right
Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combination
George Panagoulias
Patient Preference and Adherence, 2014
View PDFchevron_right
Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks
Robert Frederich
Diabetes, Obesity and Metabolism, 2011
View PDFchevron_right
Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial
Gerry Tan
International Journal of Clinical Practice, 2009
View PDFchevron_right
The Efficacy and Safety of DPP4 Inhibitors compared to Sulfonylureas as add-on Therapy to Metformin in Patients with Type 2 diabetes: A Systematic Review and Meta-analysis
Robert Tanenberg, Doyle Cummings
Diabetes Research and Clinical Practice
View PDFchevron_right
Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus
Jasmine Gonzalvo
Clinical Therapeutics, 2011
View PDFchevron_right
Tolerability of saxagliptin in patients with inadequately controlled type 2 diabetes: results from 6 phase III studies
Jaime Davidson
Journal of managed care pharmacy : JMCP, 2014
View PDFchevron_right
Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment
Ivan Rychlík
Diabetes, Obesity and Metabolism, 2011
View PDFchevron_right
Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis
Naghmeh Foroutan
Clinical and Investigative Medicine, 2016
View PDFchevron_right
Combination Therapy with a Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Metformin Markedly Improves HbA1c Levels in Japanese Patients with Type 2 Diabetes Mellitus
Keiko Arai
Japanese clinical medicine, 2012
View PDFchevron_right
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
Mark Kipnes
Diabetes, Obesity and Metabolism, 2009
View PDFchevron_right
Impact of baseline characteristics on glycemic effects of add‐on saxagliptin or acarbose to metformin therapy: subgroup analysis of the SMART study in Chinese patients with type 2 diabetes mellitus
Liya Shen
Journal of Diabetes Investigation, 2020
View PDFchevron_right
Efficacy and Safety of the Dipeptidyl Peptidase4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
michael wu
Diabetes Care, 2006
View PDFchevron_right
Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
Daisuke Yabe
View PDFchevron_right
Saxagliptin: A Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
jay shubrook
Clinical medicine insights. Endocrinology and diabetes, 2011
View PDFchevron_right
Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial
Burkhard Göke
International Journal of Clinical Practice, 2010
View PDFchevron_right
Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
Kausik Ray
New England Journal of Medicine, 2013
View PDFchevron_right
Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
natalia gaibu
Diabetes Therapy, 2013
View PDFchevron_right
Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
Jaime Davidson
Circulation, 2014
View PDFchevron_right
Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
Vincent Woo
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
View PDFchevron_right
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitor Compared to Sulphonylurea in Type II Diabetes Patients Inadequately Controlled with Metformin Alone
Manoj Karki
Journal of Universal College of Medical Sciences
View PDFchevron_right
Add-on saxagliptin improves glycemic status among uncontrolled type 2 diabetes mellitus
Butungeshwar Pradhan
International Journal of Research in Medical Sciences, 2018
View PDFchevron_right
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
Robert Frederich
Cardiovascular Diabetology, 2012
View PDFchevron_right